Letter to the Editor: Levetiracetam as an Alternative for Refractory Confusional Syndromes: A Case Series

Bruera E , Yennurajalingam S . Palliative care in advanced cancer patients: How and when? Oncologist, 2012; 17(2):267–273; doi: 10.1634/theoncologist.2011-0219

Henson LA , Maddocks M , Evans C , et al. Palliative care and the management of common distressing symptoms in advanced cancer: Pain Breathlessness, Nausea and Vomiting, and Fatigue. J Clin Oncol, 2020; 38(9):905–914; doi: 10.1200/JCO.19.00470

Rousseau P . Palliative sedation in the management of refractory symptoms. J Support Oncol, 2004; 2(2):181–186; doi: 10.1089/jpm.2005.8.10

Lambert K , NHS Foundation Trust. Subcutaneous Levetiracetam (“Keppra”) in Palliative and End of Life Care. January 2021 (Review January 2023). Available from: https://northyorkshireccg.nhs.uk/wp-content/uploads/2021/02/Subcutaneous-Levetiracetam-in-Palliative-and-End-of-Life-Care-January-2021.pdf [Last accessed: September 26, 2024].

Contreras-Garcia IJ , Cardenas-Rodriguez N , Romo-Mancillas A , et al. Levetiracetam Mechanisms of Action: From Molecules to Systems. Pharmaceuticals (Basel), 2022; 15(4):475; doi: 10.3390/ph1504047